ORKA
HealthcareOruka Therapeutics, Inc. · Biotechnology · $2B
What is Oruka Therapeutics, Inc.?
Oruka Therapeutics is a clinical-stage biotechnology company focused on developing monoclonal antibody treatments for inflammatory skin conditions and related immunology indications. Headquartered in Menlo Park, California, the company is building a targeted pipeline around dermatology.
Oruka Therapeutics is working to advance novel monoclonal antibody therapies for plaque psoriasis and other inflammation and immunology conditions. The company generates no commercial revenue at this stage — its value is tied entirely to the clinical progress of its pipeline candidates, ORKA-001 and ORKA-002. Like many clinical-stage biotechs, Oruka depends on capital markets and partnerships to fund its research and development activities.
Oruka Therapeutics was founded in 1997 and is based in Menlo Park, California.
- ORKA-001: monoclonal antibody candidate targeting plaque psoriasis
- ORKA-002: pipeline candidate for inflammation and immunology indications
- Monoclonal antibody platform focused on dermatology and I&I diseases
Is ORKA a Good Stock to Buy?
UQS Score rates ORKA as Poor overall, reflecting the early-stage nature of the business across most quality dimensions.
The one area where ORKA stands out relative to its profile is Risk, which is rated Good — suggesting the company's balance sheet or near-term financial runway is relatively manageable for a clinical-stage biotech.
Quality, Moat, and Growth are all rated Weak, which is typical for pre-revenue biotechs with unproven pipelines. Valuation is rated Elevated, meaning the market may already be pricing in optimistic outcomes.
See the complete pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does ORKA pay dividends?
Yes — Oruka Therapeutics, Inc. pays a dividend.
Oruka Therapeutics is listed as paying a regular dividend, which is unusual for a clinical-stage biotech with no commercial revenue. Investors should verify the current dividend status and yield category directly with the company's investor relations materials, as dividend policies at early-stage companies can change with funding needs.
When does ORKA report earnings?
Oruka Therapeutics reports earnings on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue clinical-stage company, quarterly results primarily reflect research and development spending and cash burn rather than top-line growth. Pipeline milestones and clinical trial updates tend to move the stock more than earnings beats or misses.
For the most recent quarter's results and guidance, visit Oruka Therapeutics' investor relations page directly.
ORKA Price History
+206.4% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Oruka Therapeutics, Inc.?
Based on Oruka Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
ORKA Long-term Outlook
With Growth and Quality both rated Weak, Oruka's near-term fundamental outlook is heavily dependent on clinical trial outcomes rather than organic business expansion. The Good Risk rating provides some reassurance about financial stability in the short run, but the Elevated Valuation suggests the stock may already reflect speculative upside. Progress on ORKA-001 or ORKA-002 would be the primary catalyst for any re-rating.
Growth drivers
- Positive clinical trial data for ORKA-001 or ORKA-002
- Potential partnerships or licensing deals in the I&I space
- Expansion of pipeline into additional inflammatory indications
Key risks
- Clinical trial failure or delays for lead pipeline candidates
- Elevated valuation leaves limited margin of safety if data disappoints
- Ongoing cash burn with no commercial revenue to offset R&D costs
ORKA vs Peers
Oruka Therapeutics operates in a competitive biotech landscape alongside other specialty and clinical-stage companies targeting similar therapeutic areas.
Ascentage focuses on oncology and hematology rather than dermatology, giving it a different risk and pipeline profile compared to Oruka.
ADMA is a commercial-stage plasma-derived biologics company, meaning it already generates product revenue — a contrast to Oruka's pre-revenue status.
Zai Lab operates across oncology and immunology with a broader commercial presence in China, offering a different geographic and pipeline diversification profile.
Frequently Asked Questions
What does Oruka Therapeutics do?
Oruka Therapeutics is a clinical-stage biotechnology company developing monoclonal antibody therapies for plaque psoriasis and other inflammation and immunology conditions. Its pipeline centers on two candidates, ORKA-001 and ORKA-002. The company has no commercial products on the market yet and funds operations through capital markets.
Does ORKA pay dividends?
Oruka Therapeutics is listed as paying a regular dividend, which is atypical for a pre-revenue clinical-stage biotech. Investors should confirm the current dividend policy and any recent changes directly through the company's investor relations page, as early-stage companies can alter dividend practices based on cash needs.
When does ORKA report earnings?
Oruka Therapeutics follows a standard quarterly earnings schedule for US-listed companies. Because it is pre-revenue, results focus on R&D expenditure and cash position rather than sales growth. Check the company's investor relations page for the most current reporting calendar.
Is ORKA a good stock to buy?
UQS Score rates ORKA as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars. The Good Risk rating offers some reassurance, but the Elevated Valuation means the stock may already price in optimistic pipeline outcomes. The full pillar breakdown is available to UQS Pro members.
Is ORKA overvalued?
The UQS Valuation pillar for ORKA is rated Elevated, suggesting the current market price may reflect speculative expectations around pipeline success. For a pre-revenue biotech, valuation is inherently forward-looking and sensitive to clinical data outcomes.
How does ORKA compare to its competitors?
Compared to peers like ADMA Biologics — which already generates commercial revenue — Oruka is at an earlier stage of development. Competitors such as Zai Lab and Ascentage Pharma operate across broader therapeutic areas. Oruka's narrow focus on dermatology and I&I is both a differentiator and a concentration risk.
What is ORKA's market cap bracket?
Oruka Therapeutics is classified as a mid-cap company. This places it in a range where institutional interest is possible, but the stock still carries the binary risk profile typical of clinical-stage biotechs without commercial revenue.
Who founded Oruka Therapeutics?
Oruka Therapeutics was founded in 1997. For detailed founding history and executive leadership information, the company's official website and SEC filings are the most reliable sources.
Is ORKA a long-term quality investment?
As a long-term quality indicator, ORKA's Poor UQS Score and Weak ratings across Quality, Moat, and Growth suggest the business has not yet demonstrated the durable fundamentals associated with long-term compounders. Long-term prospects hinge on clinical success and eventual commercialization of its pipeline.
What is the main competitive advantage of Oruka Therapeutics?
Oruka's focus on monoclonal antibody development for plaque psoriasis and related conditions represents a targeted scientific approach in a large and growing therapeutic market. However, the UQS Moat pillar is rated Weak, indicating that durable competitive advantages have not yet been established at this stage of development.
What sector does ORKA belong to?
Oruka Therapeutics belongs to the Healthcare sector, specifically within biotechnology. It is focused on immunology and dermatology, developing treatments for inflammatory conditions such as plaque psoriasis through its monoclonal antibody pipeline.
Unlock Full ORKA Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare ORKA against biotech peers side by side
- ✓Track pipeline-driven valuation and risk signals
- ✓Get the full analyst-grade quality profile for ORKA
Pro Analysis
ORKA — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 17.7 | 0.0 | 13.0 | 18.5 | 71.7 | 0.0 | 0.0 |
| Apr 22, 2026 | 17.7 | 0.0 | 13.0 | 18.5 | 71.4 | 0.0 | -0.9 |
| Apr 2, 2026 | 18.6 | 0.0 | 13.0 | 23.1 | 71.4 | 0.0 | — |
ORKA — Pillar Breakdown
Quality
— 0.0/100 (25%)Oruka Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 18.5/100 (20%)Oruka Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 71.7/100 (15%)Oruka Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Oruka Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)Oruka Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for ORKA.
Score Composition
Financial Data
More Stock Analysis
How is the ORKA UQS Score Calculated?
The UQS (Unified Quality Score) for Oruka Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Oruka Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Oruka Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.